Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter,open-label trial to evaluate activity and safety of the investigational
intensive in HIV+ patients with Burkitt's lymphoma.
Experimental treatment consists of an induction phase followed by a consolidation or
intensified phase according to tumor response.
Until recently, the immuno-compromised state of patients with concomitant HIV/AIDS and BL was
thought to limit the ability to administer intensive chemotherapeutic regimens due to
infection rate. However, the advent of highly active antiretroviral therapy (HAART) and
evidence in diffuse large B-cell lymphomas that HIV-positive patients can tolerate standard
chemotherapeutic regimens with improved outcomes have led investigators to treat HIV-positive
patients with the same intensive chemotherapy regimens used to treat immuno-competent
patients. Data suggest that these current approaches, along with supportive care, may result
in improved patient outcomes, similar to those in the immuno-competent patient population.